

Thomas J Kaley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3612265/thomas-j-kaley-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

5,084
citations

27
h-index

47
g-index

47
ext. papers

6,976
ext. citations

6.1
avg, IF

4.86
L-index

#	Paper	IF	Citations
47	Biology and Treatment of Meningiomas: A Reappraisal. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 133-146	3.1	1
46	Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. <i>Pancreatology</i> , 2021 , 21, 599-605	3.8	1
45	Neurologic Complications of Chemotherapy and Radiation Therapy 2021 , 521-537		
44	Value of [F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa050	0.9	2
43	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 429-436	5.3	13
42	Radiographic Assessment of Meningiomas 2020 , 25-33		
41	Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1571-1578	7.3	9
40	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. <i>Journal of Neuro-Oncology</i> , 2020 , 146, 339-346	4.8	4
39	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019 , 25, 477-486	50.5	490
38	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019 , 21, 26-36	1	54
37	Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 57-63	4.8	6
36	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 403-407	4.8	23
35	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019 , 25, 5537-5547	12.9	48
34	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019 , 51, 202-206	36.3	1435
33	Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. <i>CNS Oncology</i> , 2018 , 7, 7-13	4	3
32	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1702-1709	2.2	27
31	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3477-3484	2.2	139

30	Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. <i>CNS Oncology</i> , 2018 , 7, CNS19	4	2
29	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017 , 19, 1380-1390	20	
28	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017 , 7, 1018-1029	24.4	201
27	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699
26	Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. <i>Neuro-Oncology Practice</i> , 2017 , 4, 24-28	2.2	2
25	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 797-804	4	27
24	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016 , 130, 571-579	4.8	32
23	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. <i>Neuro-Oncology</i> , 2016 , 18, 735-43	1	20
22	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , 2016 , 18, 283-90	1	135
21	ACTR-43. PILOT STUDY OF OPTUNE (NOVOTTF-100A) FOR RECURRENT ATYPICAL AND ANAPLASTIC MENINGIOMA. <i>Neuro-Oncology</i> , 2016 , 18, vi11-vi11	1	2
20	ACTR-03. SAFETY AND FEASIBILITY OF RAPID RITUXIMAB INFUSIONS IN PATIENTS WITH PRIMARY CNS LYMPHOMA. <i>Neuro-Oncology</i> , 2016 , 18, vi1-vi1	1	
19	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 4786-4796	12.9	69
18	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3610-8	12.9	53
17	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 1386-92	1	39
16	Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 183-90	4.8	83
15	Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. <i>Journal of Neurosurgery</i> , 2015 , 122, 4-23	3.2	327
14	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015 , 17, 116-21	1	153
13	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015 , 125, 1403-10	2.2	190

12	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1191-202	7.3	74
11	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor VIII Status. <i>American Journal of Neuroradiology</i> , 2015 , 36, 2256-61	4.4	35
10	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. <i>Neurology</i> , 2015 , 84, 280-6	6.5	62
9	Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. <i>Clinical Cancer Research</i> , 2014 , 20, 5023-31	12.9	70
8	Whole-brain radiotherapy in patients with brain metastases from melanoma. <i>CNS Oncology</i> , 2014 , 3, 401-6	4	13
7	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , 2014 , 16, 829-40	1	134
6	Bevacizumab for acute neurologic deterioration in patients with glioblastoma. <i>CNS Oncology</i> , 2013 , 2, 413-8	4	7
5	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013 , 15, 242-50	1	71
4	Temozolomide or bevacizumab for spinal cord high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012 , 109, 385-9	4.8	35
3	Atypical and anaplastic meningiomas treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2012 , 109, 187-93	4.8	119
2	Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. <i>Neurology</i> , 2012 , 79, 1929-31	6.5	21
1	Therapy of chemotherapy-induced peripheral neuropathy. <i>British Journal of Haematology</i> , 2009 , 145, 3-14	4.5	134